The FDA has granted orphan drug designation for Lisata Therapeutics’s LSTA1 (certepetide) to treat osteosarcoma, a rare type ...
The health regulor has required related updates to other sections of the label such as warnings and precautions, ...
The FDA has approved Roche’s Alecensa for the treatment of early stage resected non-small cell lung cancer, or NSCLC, with ALK+ mutations. Roche said that the approval makes Alecensa the first and ...
The Food and Drug Administration approved the CAR-T cell therapy, Carvykti, for previously treated patients with multiple ...
Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ...
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on ...
ENHERTU, which is now FDA-approved for five indications, is a specifically engineered HER2-directed antibody drug conjugate ... to bring safe and effective cancer treatments to patients ...
The Food and Drug Administration approved Alecensa for patients with ALK-positive non-small cell lung cancer that was surgically removed. The Food and Drug Administration (FDA) has approved Alecensa ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, ...
Praluent Approved for Pediatric Patients With Heterozygous Familial Hypercholesterolemia Tryvio (aprocitentan) Endothelin receptor antagonist Treatment of hypertension in combination with other ...
The Food and Drug Administration (FDA) has issued a public notification on S.W.A.G., advising consumers against purchasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results